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ABSTRACT  
Objective: To compare disease severity classification systems for 6-month outcome prediction in patients 
with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). 
Methods: Patients with newly diagnosed AAV from 53 tertiary institutions were enrolled. Six-month 
remission, overall survival, and end-stage renal disease (ESRD)-free survival were evaluated. 
Results: According to the European Vasculitis Study Group (EUVAS)-defined disease severity, the 321 
enrolled patients were classified as follows: 14, localized; 71, early systemic; 170, generalized; and 66, 
severe disease. According to the rapidly progressive glomerulonephritis (RPGN) clinical grading system, 
the patients were divided as follows: 60, grade I; 178, grade II; 66, grade III; and 12, grade IV. According 
to the Five-Factor Score (FFS) 2009, 103, 109, and 109 patients had <1, 2, and ≥3 points, respectively. No 
significant difference in remission rates was found in any severity classification. The overall and 
ESRD-free survival rates significantly differed between grades I/II, III, and IV, regardless of renal 
involvement. Severe disease was a good predictor of 6-month overall and ESRD-free survival. The FFS 
2009 was useful to predict 6-month ESRD-free survival but not overall survival. 
Conclusions: The RPGN grading system was more useful to predict 6-month overall and ESRD-free 
survival than the EUVAS-defined severity or FFS 2009. 
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INTRODUCTION 
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including microscopic 
polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with 
polyangiitis (EGPA), are characterized by ANCA production and small vessel inflammation [1]. Previous 
reports showed interesting geographic and ethnic differences in the incidence and myeloperoxidase 
(MPO)-ANCA or peroxidase-3 (PR3)-ANCA positivity [2-4]. 
To characterize the clinical and laboratory features, and the prognosis of Japanese patients with AAV, 
we implemented a nationwide prospective cohort study of remission induction therapy in Japanese 
patients with ANCA-associated vasculitides (RemIT-JAV). In the RemIT-JAV study, we confirmed that 
MPO-ANCA-positive MPA/renal limited vasculitis RLV) was the most common form of AAV in 
Japanese patients and revealed that one-half of patients with GPA had MPO-ANCA positivity and that 
interstitial lung disease (ILD) was an important clinical manifestation in Japanese patients with AAV [5, 
6]. This high MPO-ANCA positivity in patients with GPA was also confirmed in a recent retrospective 
report [7]. In addition, we proposed MPO-ANCA positivity in AAV patients and ILD as a novel variant of 
MPA. As for clinical course, we elucidated that most Japanese patients with MPA and GPA received 
treatment with high-dose glucocorticoid and limited-dose cyclophosphamide (CY), and showed high 
remission and relapse-free survival rates. However, remission with prednisolone at <10 mg/day was 
observed only in 40% of the patients with remission at 6 months [8, 9]. To further analyze the 
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characteristics of Japanese patients with AAV, Research Committee of Intractable Vasculitis Syndrome 
and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of 
Japan collaboratively implemented a subsequent nationwide prospective cohort study of remission 
induction therapy in Japanese patients with ANCA-associated vasculitides and rapidly progressive 
glomerulonephritis (RemIT-JAV-RPGN). 
The extent and pattern of organ involvement were quite different between patients with AAV, and the 
European League Against Rheumatism (EULAR) recommends that patients with vasculitis should be 
categorized into clearly defined disease states. Currently, the European Vasculitis Study Group 
(EUVAS)-defined disease severity, Five-Factor Score (FFS), and RPGN clinical grading system could be 
used for this purpose [10-12]. The RemIT-JAV study revealed that the EUVAS-defined disease severity, 
especially the severe form, was useful for predicting poor renal and vital prognoses [9]. 
In the present study, we compared the usefulness of the three disease severity classification systems 
for predicting 6-month outcome in patients with AAV enrolled in the RemIT-JAV-RPGN study. 
 
MATERIALS AND METHODS 
Settings and patient population 
Database 
Fifty-three tertiary care institutions (university and referring hospitals) participated in this study and 
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enrolled consecutive patients with newly diagnosed AAV from April 2011 to March 2014. The criteria for 
enrolment in this study were as follows, which are the same as those in the RemIT-JAV study: 1) 
diagnosis of AAV by the site investigators, 2) fulfilling the criteria for primary systemic vasculitis as 
proposed by the European Medicines Agency (EMEA) algorithm [13], and 3) starting immunosuppressive 
treatment based on the discretion of the site investigators. The exclusion criteria were 1) age younger than 
20 years, 2) recurrent AAV, 3) serological evidence of hepatitis B or C virus infection, and 4) a history of 
malignancy because 3) and 4) may influence treatment selection and the prognosis of patients with AAV. 
We conducted this study according to the Declaration of Helsinki and the ethical guidelines for 
Epidemiological Research in Japan. Written informed consent was obtained from each participant, and the 
study protocol was approved by the ethics committee of each participating hospital. This study was 
registered with the University Hospital Medical Information Network Clinical Trials Registry 
(UMIN000005136). 
Data collection 
The baseline data of each patient included demographic information; general performance categorized 
using the World Health Organization performance status scale, except category 5 (death) [14]; 
comorbidities; laboratory data; disease activity according to the Birmingham Vasculitis Activity Score 
(BVAS) 2003 [15]; imaging data (e.g., findings of chest radiography, thoracic computed tomography, 
renal histology, and magnetic resonance imaging of the head); and respiratory function data. RPGN was 
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defined as an abrupt or insidious onset of macroscopic hematuria, proteinuria, anemia, and rapidly 
progressing renal failure [16]. 
At months 3, 6, 12, 18, and 24 and at relapse, the following data were collected: vital status, BVAS 
2003, laboratory data, treatments, and adverse events. The Vascular Damage Index score [17] was 
recorded at months 6, 12, and 24. Chest radiography and respiratory function data were collected at 
months 12 and 24, and thoracic computed tomography data were collected at months 3, 6, 12, and 24 in 
patients with pulmonary involvement. Observation will be completed in March 2016. 
The site investigators completed and sent the electronic case report form for each patient to the 
RemIT-JAV-RPGN data center at the Department of Medicine and Clinical Science, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Okayama, Japan. 
Outcome measures 
The primary outcome measure of the present study was cumulative remission rate within 6 months. 
Remission was defined as the complete absence of disease activity attributable to active vasculitis. The 
absence of disease activity was determined systematically using a BVAS of 0 on two occasions at least 1 
month apart according to the EULAR recommendations [18]. 
Secondary outcome measures included cumulative overall and end-stage renal disease (ESRD)-free 
survival rates at 6 months. ESRD was defined as dependence on dialysis or an irreversible increase in 
serum creatinine level of >5.6 mg/dL (500 mol/L). 
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Disease severity 
The disease severity of the enrolled patients was classified as localized, early systemic, generalized, or 
severe according to the EUVAS-defined disease severity [18]. The patients with threatened vital organ 
function were classified as having a generalized disease, and the patients with organ failure were 
classified as having severe disease. Detailed definitions of disease severity were described in our previous 
report [5]. 
We also classified the patients into 4 groups according to Japanese RPGN clinical grading [11]. The 
parameters included in RPGN clinical grading were as follows: serum creatinine level (<3 mg/dL = 0 
point, 3–6 mg/dL = 1 point, >6 mg/dL = 2 points, and dialysis dependent = 3 points), age (≤59 years = 0 
point, 60–69 years = 1 point, and ≥70 years = 2 points), lung involvement (negative = 0 point and positive 
= 2 points), and serum C-reactive protein (CRP) level (<2.6 mg/dL = 0 point, 2.6–10.0 mg/dL = 1 point, 
and >10 mg/dL = 2 points). Lung involvement was defined as presence of chest symptoms in BVAS or 
ILD. ILD was diagnosed by site investigators using chest radiography and/or thoracic computed 
tomography in the present study. The points of these 4 parameters were summed, and patients were 
divided into 4 groups as follows: grade I, 0 to 2 points; grade II, 3 to 5 points; grade III, 6 to 7 points; and 
grade IV, 8 to 9 points. 
For calculation of FFS 2009, we defined each parameter as follows: renal insufficiency was defined as 
a serum creatinine level > 1.7 mg/dL; cardiac insufficiency, as presence of cardiac symptoms in BVAS; 
Comparison of severity classification in AAV 
 
11 
 
gastrointestinal involvement, as presence of abdominal symptoms in BVAS; and ear, nose, and throat 
(ENT) involvement, as presence of ENT symptoms in BVAS. Age older than 65 years, cardiac 
insufficiency, gastrointestinal involvement, and renal insufﬁciency were accorded +1 point, and absence 
of ENT manifestations was accorded +1 point. The patients were divided into 3 groups according to the 
sum of the points of these 5 parameters as follows: <1, 2, and ≥3. 
Statistical analysis 
We used baseline and follow-up data at 3 and 6 months of the enrolled patients in this study for statistical 
analysis. Categorical variables were compared using the Fisher direct probability test, and continuous 
variables were compared using the Mann-Whitney U test. The cumulative remission, overall survival, and 
ESRD-free survival rates were analyzed using the Kaplan-Meier method and compared using the log-rank 
test.  
A p value of <0.05 was considered significant for statistical analyses. When comparing three or four 
categories, statistical significance was determined by <0.05/3 or <0.05/6 by Bonferroni correction to 
adjust for multiple testing. All statistical analyses were performed by a biostatistician using the JMP 
version 10.0.2 statistical package for Windows (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Patient characteristics 
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In total, 321 patients with AAV were initially enrolled in the RemIT-JAV-RPGN study. Using the EMEA 
algorithm, we identified 28 patients with EGPA, 53 with GPA, 198 with MPA/RLV, and 42 who were 
unclassifiable (Figure 1). The median ages of the patients with EGPA (male/female, 9/19), GPA (20/33), 
MPA/RLV (93/105), and unclassifiable disease (15/25) were 60.5, 68, 73, and 74 years, respectively 
(Table 1). The patients with MPA/RLV and unclassifiable patients were significantly older at the time 
of presentation than those with EGPA (p < 0.017 for both). A female predominance was observed for all 
AAV diseases. MPO-ANCA was positive in 42.9% of the patients with EGPA, 62.3% of those with GPA, 
and 98.5% of those with MPA/RLV. In contrast, PR3-ANCA was positive in 3.6% with EGPA, 35.9% 
with GPA, and 3.5% with MPA/RLV. Renal manifestations developed in 256 patients (79.8%). Of the 42 
unclassifiable patients, 37 (88.1%) had MPO-ANCA positivity and 31 (73.8%) had ILD.  
Disease severity classification 
Disease severity was classified using the three different classification systems (Table 2). According to the 
EUVAS-defined disease severity, 14 patients (4.3%) had localized disease, 71 (22.1%) had early systemic 
disease, 170 (53.0%) had generalized disease, and 66 (20.6%) had severe disease. The RPGN clinical 
grading system divided the patients as follows: 60 (19.0%) with grade I, 178 (56.3%) with grade II, 66 
(20.9%) with grade III, and 12 (3.8%) with grade IV. Five patients was excluded because data of CRP 
levels were missing. With the use of FFS 2009, 103 (32.1%) patients had <1 point, 109 (34.0%) had 2 
points, and the other 109 (34.0%) had >3 points. Cardiac symptom was found only in 27 AAV patients 
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(8.4%); and abdominal symptom, only in 6 AAV patients (1.9%). 
Clinical course 
Of the 321 patients, 2 (1 patient with EGPA and 1 patient with MPA) were excluded from the outcome 
analysis because follow-up data were not obtained. The median initial daily prednisolone dose was 40 
mg, and methylprednisolone pulse therapy was used in 145 (45%) patients. Concomitant CY was 
used during the initial 3 weeks of remission induction therapy in 105 (33%) patients and 
plasmapheresis was implemented in 16 (5%) patients. 
By 6 months, 22 (81.5%) of the 27 EGPA patients, 48 (90.6%) of the 53 GPA patients, 150 (76.1%) of 
the 197 MPA patients, and 40 (95.2%) of the 42 unclassifiable patients achieved remission, as defined by 
a BVAS of 0 on two occasions at least 1 month apart. A statistical difference in remission was observed 
between the disease classifications (p = 0.04). The patients with unclassifiable disease exhibited a 
significantly higher remission rate than the patients with MPA after Bonferroni correction (p = 0.006; 
Figure 2a). No statistically significant difference in remission rate was found between the groups when 
we used the other three severity classification criteria. In 29 patients who were alive at 6 months without 
achieving remission, manifestations were found in the kidney, neurological system, chest, cardiovascular 
system, and ENT in 18 (62.1%), 4 (13.8%), 3 (10.3%), 2 (6.9%), and 1 (3.5%), respectively, at 6 months. 
Fifteen deaths were reported during the 6-month observation period (14 MPA patients and 1 GPA 
patients). The causes of death reported by the site investigators were vasculitis (3 patients), infection (7 
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patients), and others (cardiovascular in 2 patients, gastrointestinal bleeding in 2 patients, and subacute 
fulminant hepatic failure in 1 patient). In terms of overall survival rate, the patients with MPA tended to 
have worse prognosis than those with EGPA, GPA, and unclassifiable disease, but the differences were 
not statistically significant (p = 0.07; Figure 3a). In the EUVAS-defined disease severity spectrum, 
survival rate significantly differed across the groups (p = 0.005). The patients with severe disease had a 
poorer prognosis than those with generalized disease, with a statistically significant difference after 
Bonferroni correction (p = 0.0006; Figure 3b). Using the RPGN clinical grading, we found a significant 
difference in survival rate across the four groups (p < 0.0001). The patients categorized as grade I had a 
statistically better prognosis than those categorized as either grade III (p = 0.0076) or IV (p < 0.0001). 
The patients categorized as grade II had statistically better prognosis than those categorized as either 
grade III (p = 0.004) or IV (p < 0.0001). The patients categorized as grade III tended to have better 
prognosis than those categorized as grade IV, but the difference was not significant after Bonferroni 
correction (p = 0.03). No significant difference in survival rate according to FFS 2009 was found between 
the three groups (p = 0.09). 
Twenty-nine cases of ESRD developed during the observation period (25 patients with MPA, 2 with GPA, 
and 2 with unclassifiable disease). The median (range) time to ESRD was 26.2 days (0–173 days). As for 
EUVAS-defined disease severity, ESRD-free survival rate significantly differed between the four groups. 
The patients with severe disease showed significantly poorer renal outcome than those with early 
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systemic disease (p < 0.0001) and those with generalized disease (p < 0.0001). A statistically significant 
difference was found between the four groups when the RPGN clinical grading was used (p < 0.0001), 
and all intergroup comparisons, except grades I and II, showed significant differences after Bonferroni 
correction (grade I vs grade III, p = 0.0012; grade I vs grade IV, p < 0.0001; grade II vs grade III, p < 
0.0001; grade II vs grade IV, p < 0.0001; and grade III vs grade IV, p < 0.0001, respectively). A 
statistically significant difference in ESRD-free survival was found between the three FFS 2009 groups (p 
< 0.0001). Patients with >3 points in the FFS 2009 showed significantly poorer renal outcome than the 
other 2 groups after Bonferroni correction (vs patients with <1 point in the FFS 2009, p<0.0001 and vs 
patients with 2 points in the FFS 2009, p=0.001, respectively). 
 
DISCUSSION 
This is the first prospective cohort study that compared between several disease severity classification 
systems in AAV patients. The RPGN clinical grading system was a good predictor of 6-month overall 
survival and ESRD-free survival not only in RPGN patients but also in AAV patients. 
In both this study and the RemIT-JAV study, the majority of the patients were positive for 
MPO-ANCA and diagnosed with MPA. The proportion of MPA patients, however, was higher (60% vs. 
50%), and the proportion of patients with unclassifiable disease were lower (13% vs. 20%) in the 
RemIT-JAV-RPGN study than in the RemIT-JAV study. Almost same number of the rheumatologists 
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and the nephrologists participated in the RemIT-JAV-RPGN study while more rheumatologists 
participated than the nephrologists in the RemIT-JAV study, which probably accounts for the 
difference of the proportion of each disease between the two studies. Because numbers of the 
board-certified nephrologists and rheumatologists are substantially equal in Japan, the proportion of 
each disease in the RemIT-JAV-RPGN study may reflect the real-world situation in Japan more accurately 
than that in the RemIT-JAV study. 
The 6-month remission rate in the present study was 10% lower than that in the RemIT-JAV study 
(76% in RemIT-JAV-RPGN vs 85% in RemIT-JAV). Renal manifestations were observed at 6 months in 
62.1% of the patients who did not achieve remission. Considering that the patients with renal damage 
exhibited large fluctuation in serum creatinine or urinary protein level, making a precise judgment of the 
vasculitis activity for the renal components of the BVAS system seemed difficult for the site investigators. 
The higher frequency of renal involvement in the present study (80% in RemIT-JAV-RPGN vs 70% in 
RemIT-JAV) may have affected the lower remission rate in the present study. 
The RPGN clinical grading system was a good predictor of 6-month overall and ESRD-free survival 
in the present study. The RPGN clinical grading was created with 844 Japanese patients (including 502 
patients with MPA/RLV) with RPGN from 1989 to 1998 and validated in 888 patients with RPGN from 
1999 to 2007 (including 587 patients with MPA/RLV) [11]. The overall and ESRD-free survival rates 
significantly differed between grades I/II, III, and IV in this study even though some patients did not have 
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renal involvement. A previous report also showed that score based on this system was a good predictor of 
mortality in patients with MPO-AAV [19]. As for the EUVAS-defined disease severity, severe disease was 
a good predictor of 6-month overall and ESRD-free survival, but the difference of these outcomes was not 
apparent among limited, early systemic, and generalized diseases. The EUVAS-defined disease severity 
was categorized based on the extent of organ damage and renal function. Organ failure classified as 
severe disease was defined according to the presence of any of the following BVAS manifestations: 
massive hemoptysis/alveolar hemorrhage, respiratory failure, congestive cardiac failure, ischemic 
abdominal pain, or stroke. These symptoms may be good predictors of 6-month survival because they are 
potentially fatal if not responsive to treatment. Categorization according to FFS 2009 was useful to 
predict 6-month ESRD-free survival but not overall survival. This may be explained by the fact that 
cardiac or abdominal manifestations, which are incorporated in FFS 2009, were rarer in the AAV patients 
enrolled in the RemIT-JAV-RPGN study than those enrolled in a Western clinical study [20]. 
Our study has several limitations. First, selection bias should be considered because this study was 
performed in university and referral hospitals in Japan. However, patients with AAV are frequently 
referred to specialists in Japan and 53 institutions participated in the RemIT-JAV-RPGN; thus, the results 
of this study have generalizability to some extent. Second, our data might have been affected by 
indication bias, which could influence treatment selection and outcomes of the patients in each 
classification group of disease severity therefore further analysis need to be elucidate the effectiveness 
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and the safety of the treatment for AAV. Third, the 6-month observation period could be too short to 
evaluate true outcomes of AAV. 
In conclusion, the Japanese RPGN clinical grading system was more useful for predicting 6-month 
overall and ESRD-free survival in Japanese AAV patients than the EUVAS-defined disease severity or 
FFS 2009. 
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FIGURE LEGENDS 
Figure 1 Classification of the 321 patients with ANCA-associated vasculitis according to the EMEA 
algorithm in this cohort study. 
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; EGPA, eosinophilic 
granulomatosis with polyangiitis; EMEA, European Medicines Agency; GPA, granulomatosis with 
polyangiitis; MPA, microscopic polyangiitis; RLV, renal-limited vasculitis. 
 
Figure 2. Cumulative remission rates according the EUVAS-disease severity, RPGN clinical grading, 
and Five-Factor Score 2009 disease classification systems 
Cumulative remission rates were analyzed using the Kaplan-Meier method. The log-rank test was used 
for intergroup comparison. (a) Remission rates according to disease classification. (b) Remission rates 
according to the EUVAS-defined disease severity. (c) Remission rates according to the RPGN clinical 
grading. (d) Remission rates according to the Five-Factor Score 2009. 
 
Figure 3. Cumulative overall survival rates according to the EUVAS-disease severity, RPGN clinical 
grading, and Five-Factor Score 2009 disease classification systems 
Cumulative survival rates were analyzed using the Kaplan-Meier method. The log-rank test was used for 
intergroup comparison. (a) Survival rates according to disease classifications. (b) Survival rates according 
to EUVAS-defined disease severity. (c) Survival rates according to the RPGN clinical grading. (d) 
Survival rates according to the Five-Factor Score 2009. 
 
Figure 4. Cumulative ESRD-free survival rate according to the EUVAS-disease severity, RPGN 
clinical grading, and Five-Factor Score 2009 disease classification systems 
Cumulative ESRD-free survival rates were analyzed using the Kaplan-Meier method. The log-rank test 
was used for intergroup comparison. (a) ESRD-free survival rates according to disease classification. (b) 
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ESRD-free rates according to the EUVAS-defined disease severity. (c) ESRD-free survival rates 
according to the RPGN clinical grading. (d) ESRD-free survival rates according to the Five-Factor Score 
2009. 
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Table 1 Demographic characteristics of the patients with AAV disease 
 EGPA 
(n = 28) 
GPA 
(n = 53) 
MPA/RLV 
(n = 198) 
Unclassifiable 
(n = 42) 
Male/female, n 9/19 20/33 93/105 17/25 
Mean (median) age (years)#,‡ 57.4 ± 16.0 
(60.5) 
66.8± 15.5 
(68) 
70.5 ± 12.2 
(73) 
72.8 ± 10.1 
(74) 
MPO-ANCA positive#,†,‡,§,¶ 12 (42.9) 33 (62.3) 195 (98.5) 37 (88.1) 
PR3-ANCA positive*,†,‡,§ 1 (3.6) 19 (35.9) 7 (3.5) 3 (7.1) 
ANCA negative*,# 16 (57.1) 4 (7.6) 2 (1.0) 3 (7.1) 
Serum creatinine (mg/dL)*,#,†,¶ 
General performance 
0/1/2/3/4  
RPGN*,#,†,‡,¶ 
0.63 ± 0.18 
 
3/9/5/10/1 
0 (0) 
1.60 ± 1.77 
 
7/23/10/11/2 
19 (35.9) 
3.20 ± 3.20 
 
41/82/31/31/13 
144 (72.7) 
1.27 ± 1.48 
 
4/21/8/8/1 
8 (19.1) 
Interstitial lung disease†,‡,§,¶ 8 (28.6) 10 (18.9) 89 (45.0) 31 (73.8) 
Values are expressed as mean ± standard deviation or n (%) unless otherwise noted. Comparisons 
between the EGPA, GPA, and MPV/RLV groups were made using the Mann-Whitney U test. Statistical 
significance was determined based on <0.05/6 using Bonferroni correction: *EGPA versus GPA. #EGPA 
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versus MPA/RLV. †GPA versus MPA/RLV. ‡EGPA versus unclassifiable AAV. §GPA versus 
unclassifiable AAV. ¶MPA/RLV versus unclassifiable AAV. 
AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; EGPA, eosinophilic 
granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic 
polyangiitis; MPO, myeloperoxidase; PR3, peroxidase-3; RLV, renal-limited vasculitis; RPGN, rapidly 
progressive glomerulonephritis. 
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Table 2 Disease severity classification according to EUVAS-defined disease severity, RPGN clinical 
grading, and Five Factor Score 2009 
 
 EGPA GPA MPA/RLV Unclassifiable 
EUVAS-defined disease severity (n = 28) (n = 53) (n = 198) (n = 42) 
Localized 0 (0) 6 (11.3) 7 (3.5) 1 (2.4) 
Early systemic 1 (3.6) 7 (13.2) 45 (22.7) 18 (42.9) 
Systemic 23 (82.1) 31 (58.5) 96 (48.5) 20 (47.6) 
Severe 4 (14.3) 9 (17.0) 50 (25.3) 3 (7.1) 
RPGN clinical grading (n = 27) (n = 53) (n = 194) (n = 42) 
I 14 (51.9) 8 (15.1) 34 (17.5) 4 (9.5) 
II 11 (40.7) 32 (60.4) 107 (55.2) 28 (66.7) 
III 2 (7.4) 13 (24.5) 42 (21.7) 9 (21.4) 
IV 0 (0) 0 (0) 11 (5.7) 0 (2.4) 
Five-Factor Score 2009 (n = 28) (n = 53) (n = 198) (n = 42) 
<1 24 (85.7) 40 (75.5) 30 (15.2) 9 (21.4) 
2 3 (10.7) 12 (22.6) 67 (33.8) 27 (64.3) 
≥3 1 (3.6) 1 (1.9) 101 (51.0) 6 (14.3) 
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Values are expressed as n (%). 
EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, 
microscopic polyangiitis; MPO, myeloperoxidase; PR3, peroxidase-3; RLV, renal-limited vasculitis; 
RPGN, rapidly progressive glomerulonephritis. 
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